The introduction of experimental treatment for lysosomal storage disorders and the increasing understanding of the molecular defects behind many inborn errors have overshadowed the fact that for many affected families the best that can be offered is a rapid, accurate prenatal diagnostic service. Many conditions remain at best only partially treatable and as a consequence the majority of parents seek antenatal diagnosis in subsequent pregnancies, particularly for those disorders resulting in a poor prognosis in terms of either life expectancy or normal neurological development.
The majority of inborn errors result from a specific enzyme deficiency, but in some the primary defect is in a transport system or enzyme cofactor. In some conditions the biochemical defect is limited to specific tissues only and this serves to restrict the material available for antenatal diagnosis for these disorders. Fortunately for many inborn errors the metabolic defect is generalised and both amniotic and chorion villus cells can be used as a diagnostic tissue.
Before contemplating prenatal diagnosis it is essential that a firm biochemical diagnosis has been established in the index case. It is unsafe to rely only on a clinical or histological diagnosis as many of the inherited disorders share a similar phenotype. To ease interpretation of results obtained on the fetus it is necessary to know the heterozygote levels of enzyme activity in the parents; occasionally these are remarkably low and can lead to difficulties in ascribing fetal genotype.
The properties of some enzymes are appreciably different when studied at different times of gestation. In addition, the activity obtained from chorion villus material may be very different from that obtained on amniotic fluid cells. It is essential that the correct tissue is collected at the most appropriate time. Liaison with the laboratory staff performing the test is mandatory if mistakes are to be avoided.
Prenatal testing by analysis of fetal DNA by either a gene specific DNA probe or gene tracking using restriction fragment length polymorphisms (RFLPs) requires proband DNA for comparison. This underlies the importance of establishing fibroblast cultures from all patients diagnosed as having a metabolic disorder as well as ensuring that blood is taken from all relevant family members for DNA extraction and storage.
Most prenatal testing for metabolic disease is performed in a few specialised laboratories.
Sample requirement and techniques used in prenatal diagnosis By far the majority of antenatal diagnoses are performed on samples obtained by either amniocentesis or chorion villus biopsy. For some disorders, however, the defect is not detectable in this material and more invasive methods have been applied to obtain a diagnostic sample.
FETAL LIVER BIOPSY
Fetal liver biopsy has been performed to diagnose ornithine carbamoyl transferase deficiency and primary hyperoxaluria type 1. Glucose-6-phosphatase deficiency (glycogen storage disease type I) could also be detected by this method. The technique, however, is invasive and can be performed by only a few highly specialised fetal diagnostic units.
FETAL BLOOD SAMPLING
Fetal blood sampling could be used for the antenatal diagnosis of many inborn errors. The sample, however, tends to be collected late in pregnancy and the technique is probably best reserved as a back up in case of failed amniotic fluid cell culture.
AMNIOCENTESIS
Amniocentesis has been the most common procedure for antenatal diagnosis of metabolic disease. Both the cell free amniotic fluid and cultured and uncultured amniotic fluid cells are useful in diagnosis.
The procedure is usually performed at 15-16 weeks' gestation and most analyses can be performed within two to three weeks of culture. First trimester amniocentesis has been attempted to allow earlier diagnosis, but the smaller sample size and possible variation in enzyme activity at the earlier stage of pregnancy have introduced variables that need to be studied before the technique can be widely applied.
(1) Cell free amniotic fluid can be used to detect a number of intermediary metabolites in many inborn errors. Where possible this technique should be backed by specific enzyme analysis, but for many conditions does allow a quick diagnosis. It is particularily relevant for organic acid disorders using stable isotope dilution gas chromatography with mass spectrometry and selected ion monitoring.
In mucopolysaccharide disorders the pattern 
